Gentrack seeks to calm naysayers, clawing back some losses.
Scales predicts protein division will become bigger than Mr Apple in the long run.
Management at beleaguered company fronts. 'Without question, it’s been a very challenging few days for everybody.'
Cancer diagnostics company reveals Medicare’s coverage accounted for 77% of its total operating revenue in 2023.
Shares in trading halt pending completion of $750m underwritten placement at $9.20 a share.
The early childhood education group intends to re-domicile on the ASX.
Pathway back to coverage of Cxbladder product at least three years away, shares expected to sharply fall.
Analysts say it could cost the company between 5% to 10% of ebitda.
Analysts label unfavourable Medicare decision very material for diagnostics company.
China’s regulator re-registers Synlait Dunsandel plant for China infant formula exports.
